{"id":"s-1-plus-cisplatin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"S-1 works by inhibiting thymidylate synthase, which is essential for DNA synthesis and repair. Cisplatin, on the other hand, forms platinum-DNA adducts that interfere with DNA replication and transcription, ultimately leading to cell death. This combination of mechanisms allows S-1 plus cisplatin to target rapidly dividing cancer cells.","oneSentence":"S-1 is a fluoropyrimidine derivative that inhibits thymidylate synthase, while cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:03.339Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT01878617","phase":"PHASE2","title":"A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-23","conditions":"Medulloblastoma","enrollment":660},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT07085234","phase":"PHASE2","title":"Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-07-30","conditions":"Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy","enrollment":30},{"nctId":"NCT07080437","phase":"","title":"An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Three Gorges Hospital of Chongqing University","startDate":"2021-03-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":40},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06811844","phase":"PHASE2","title":"Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-02-25","conditions":"Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy","enrollment":208},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT03406299","phase":"PHASE2","title":"Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-19","conditions":"Biliary Tract Neoplasms","enrollment":92},{"nctId":"NCT06422858","phase":"PHASE2","title":"Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-05-20","conditions":"Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT06903273","phase":"PHASE2","title":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Biliary Tract Cancer (BTC)","enrollment":35},{"nctId":"NCT06730373","phase":"PHASE2","title":"First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-10-17","conditions":"HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma","enrollment":110},{"nctId":"NCT01286766","phase":"PHASE2","title":"Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT03814759","phase":"PHASE2","title":"Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-12-12","conditions":"Gastric Adenocarcinoma","enrollment":102},{"nctId":"NCT01285557","phase":"PHASE3","title":"Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2011-04-14","conditions":"Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction","enrollment":361},{"nctId":"NCT00400179","phase":"PHASE3","title":"A Safety and Efficacy Study in Patients With Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2005-05","conditions":"Gastric Cancer","enrollment":1053},{"nctId":"NCT00398307","phase":"PHASE1","title":"Evaluating Patients With Varying Degrees of Renal Function","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2006-02","conditions":"Renal Impairment","enrollment":24},{"nctId":"NCT00398424","phase":"PHASE1","title":"Evaluating Patients With Impaired Hepatic Function","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2006-02","conditions":"Impaired Hepatic Function","enrollment":24},{"nctId":"NCT00072787","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2003-10","conditions":"Gastric Cancer","enrollment":41},{"nctId":"NCT00651833","phase":"PHASE2","title":"Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2005-02","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT02995850","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-02-22","conditions":"Gastric Cancer With Peritoneal Metastasis (PCI<12)","enrollment":25},{"nctId":"NCT03769935","phase":"PHASE2","title":"Maintenance Therapy for Small-cell Lung Cancer","status":"COMPLETED","sponsor":"Qingdao Central Hospital","startDate":"2017-01-01","conditions":"Progression Free Survival","enrollment":90},{"nctId":"NCT05497739","phase":"PHASE2","title":"Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-06-28","conditions":"Gastric Cancer","enrollment":68},{"nctId":"NCT03946969","phase":"PHASE2","title":"Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2019-05-09","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT03617133","phase":"PHASE2","title":"Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2016-04","conditions":"Uterine Cervical Neoplasms","enrollment":1000},{"nctId":"NCT02322593","phase":"PHASE3","title":"Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2014-12","conditions":"Gastric Cancer","enrollment":711},{"nctId":"NCT03051373","phase":"PHASE2","title":"Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2017-04-01","conditions":"Carcinoma, Transitional Cell","enrollment":108},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT02862535","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-09-20","conditions":"Gastric Adenocarcinoma","enrollment":36},{"nctId":"NCT02114359","phase":"PHASE3","title":"Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-02","conditions":"Gastric Cancer","enrollment":111},{"nctId":"NCT04465968","phase":"PHASE3","title":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2020-09-01","conditions":"Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB, Non Small Cell Lung Cancer Stage III","enrollment":84},{"nctId":"NCT02495493","phase":"PHASE2","title":"S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2013-07","conditions":"Gastric Adenocarcinoma","enrollment":42},{"nctId":"NCT00915382","phase":"PHASE3","title":"Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-01","conditions":"Advanced Gastric Cancer","enrollment":625},{"nctId":"NCT00806117","phase":"PHASE3","title":"Comparison of Different Subsequent Treatments After Radical Surgery","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2008-02-25","conditions":"Cervical Cancer","enrollment":1080},{"nctId":"NCT00770874","phase":"PHASE3","title":"Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2008-09","conditions":"Cervical Cancer","enrollment":375},{"nctId":"NCT02182778","phase":"PHASE3","title":"GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2014-07-09","conditions":"Biliary Tract Cancer","enrollment":246},{"nctId":"NCT01821248","phase":"PHASE2","title":"A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis","status":"UNKNOWN","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2013-07-23","conditions":"Biliary Tract Cancer","enrollment":25},{"nctId":"NCT03825328","phase":"PHASE2","title":"A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )","status":"UNKNOWN","sponsor":"Yanqiao Zhang","startDate":"2019-01-30","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT01283204","phase":"PHASE2","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03-09","conditions":"Recurrent or Metastatic Gastric Cancer","enrollment":180},{"nctId":"NCT01783951","phase":"PHASE1, PHASE2","title":"Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-02-01","conditions":"Gastric Cancer","enrollment":63},{"nctId":"NCT02359058","phase":"PHASE1","title":"A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-02","conditions":"Stomach Neoplasms","enrollment":18},{"nctId":"NCT03061058","phase":"PHASE3","title":"Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2013-04-01","conditions":"Stomach Neoplasms, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":240},{"nctId":"NCT02913066","phase":"PHASE2","title":"S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Mianyang Central Hospital","startDate":"2016-09","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":88},{"nctId":"NCT03179579","phase":"PHASE3","title":"Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer","status":"UNKNOWN","sponsor":"Shu-Zhong Cui","startDate":"2017-08-01","conditions":"Gastric Cancer, Peritoneal Carcinomatosis","enrollment":88},{"nctId":"NCT01704690","phase":"PHASE2, PHASE3","title":"Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer","status":"TERMINATED","sponsor":"Peking University","startDate":"2012-08","conditions":"Esophageal Cancer","enrollment":4},{"nctId":"NCT02878889","phase":"PHASE2","title":"A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-08","conditions":"Nasopharyngeal Carcinoma","enrollment":53},{"nctId":"NCT00252161","phase":"PHASE3","title":"A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer","status":"COMPLETED","sponsor":"Haruhiko Fukuda","startDate":"2005-11","conditions":"Gastric Neoplasm","enrollment":316},{"nctId":"NCT00142350","phase":"PHASE3","title":"A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Japan Clinical Oncology Group","startDate":"2000-11","conditions":"Gastric Cancer","enrollment":690},{"nctId":"NCT01854749","phase":"PHASE2","title":"S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":57},{"nctId":"NCT02677597","phase":"PHASE3","title":"Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":268},{"nctId":"NCT01671449","phase":"PHASE3","title":"S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Min-Hee Ryu","startDate":"2012-12","conditions":"Gastric Cancer","enrollment":338},{"nctId":"NCT02586753","phase":"PHASE2","title":"Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus","status":"UNKNOWN","sponsor":"Mianyang Central Hospital","startDate":"2015-12","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":2},{"nctId":"NCT01679340","phase":"PHASE2","title":"A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery","status":"UNKNOWN","sponsor":"Peking University","startDate":"2011-04","conditions":"Gastric Cancer","enrollment":160},{"nctId":"NCT02396498","phase":"PHASE3","title":"SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 Gastrectomy","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2014-04","conditions":"Stage Ⅲ Gastric Cancer","enrollment":270},{"nctId":"NCT00553696","phase":"PHASE1","title":"Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Stomach Neoplasms","enrollment":27},{"nctId":"NCT02370849","phase":"PHASE2","title":"Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2009-10","conditions":"Stomach Neoplasms","enrollment":2},{"nctId":"NCT02291211","phase":"PHASE2","title":"S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2014-09","conditions":"Stage IV Gastric Cancer","enrollment":60},{"nctId":"NCT02223611","phase":"PHASE2","title":"Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer Stage Ⅱ, Non-small Cell Lung Cancer Stage ⅢA","enrollment":100},{"nctId":"NCT01284413","phase":"PHASE1, PHASE2","title":"Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2010-12","conditions":"Biliary Tract Cancer","enrollment":68},{"nctId":"NCT01388790","phase":"PHASE2","title":"Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-06","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT00088816","phase":"PHASE2","title":"S-1 and Cisplatin Before Surgery in Treating Patients With Stage IV Gastric Cancer","status":"UNKNOWN","sponsor":"Kyoto University","startDate":"2003-04","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT00182611","phase":"PHASE3","title":"S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer","status":"COMPLETED","sponsor":"Kyoto University","startDate":"2004-04","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT01736410","phase":"PHASE2","title":"A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2010-05","conditions":"HER 2 Positive Advanced Gastric Cancer","enrollment":30},{"nctId":"NCT00663741","phase":"PHASE1","title":"Sorafenib Gastric Cancer Asian Phase I Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-05","conditions":"Gastric Cancer","enrollment":13},{"nctId":"NCT01283217","phase":"PHASE3","title":"Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2010-03","conditions":"Gastric Adenocarcinoma","enrollment":166},{"nctId":"NCT01824004","phase":"PHASE2","title":"Postoperative Chemoradiotherapy With S-1 in Gastric Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2009-04","conditions":"Gastric Cancer","enrollment":46},{"nctId":"NCT01747707","phase":"PHASE2","title":"Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2012-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":40},{"nctId":"NCT01645748","phase":"PHASE2","title":"Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2008-10","conditions":"Head and Neck Cancer","enrollment":35},{"nctId":"NCT01426646","phase":"PHASE2","title":"S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer","status":"UNKNOWN","sponsor":"Kyungpook National University Hospital","startDate":"2011-09","conditions":"Gastric Cancer","enrollment":218},{"nctId":"NCT00659113","phase":"PHASE2","title":"S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2008-03","conditions":"Esophageal Cancer","enrollment":32},{"nctId":"NCT01375972","phase":"PHASE2","title":"Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2008-03","conditions":"Metastatic Biliary Cancer","enrollment":92},{"nctId":"NCT01198392","phase":"PHASE3","title":"Trial of S-1 Plus Cisplatin in Gastric Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2008-09","conditions":"Gastric Cancer","enrollment":270},{"nctId":"NCT00960349","phase":"PHASE1","title":"Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Gastric Cancer","enrollment":14},{"nctId":"NCT00625937","phase":"PHASE2","title":"Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2006-11","conditions":"Head and Neck Cancer","enrollment":46},{"nctId":"NCT00874328","phase":"PHASE1, PHASE2","title":"A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2008-10","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":74},{"nctId":"NCT00980603","phase":"PHASE2","title":"Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2008-11","conditions":"Gastric Cancer","enrollment":144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":288,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TS-1","cisplatin","Tegafur,Gimeracil and Oteracil Potassium Capsules"],"phase":"phase_3","status":"active","brandName":"S-1 plus Cisplatin","genericName":"S-1 plus Cisplatin","companyName":"Taiho Pharmaceutical Co., Ltd.","companyId":"taiho-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"S-1 is a small molecule used in cancer treatment, and it is often combined with Cisplatin in clinical trials for various types of cancer, including Nasopharyngeal Carcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, and Gastroesophageal Junction Cancer. The combination of S-1 and Cisplatin has been studied in clinical trials as a potential treatment for these cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}